Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

NCT00095693 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Anaplastic Thyroid Cancer
Insular Thyroid Cancer
Recurrent Thyroid Cancer
Stage III Follicular Thyroid Cancer
Stage III Papillary Thyroid Cancer
Stage IV Follicular Thyroid Cancer
Stage IV Papillary Thyroid Cancer

Interventions

DRUG: sorafenib tosylate
OTHER: laboratory biomarker analysis
OTHER: pharmacological study
RADIATION: fludeoxyglucose F 18
PROCEDURE: positron emission tomography
PROCEDURE: dynamic contrast-enhanced magnetic resonance imaging

Sponsor

National Cancer Institute (NCI)